Lytix Biopharma is delighted to announce that some of the world’s leading experts in cancer immunotherapy have accepted to join our newly formed Scientific and Clinical Advisory Board to guide Lytix Biopharma on the optimal development of our lead candidate, an oncolytic peptide immune-therapy, LTX-315.
The following experts will constitute our Scientific and Clinical Advisory Board:
Prof. Robert Andtbacka
- M.D., Surgical oncologist, Salt Lake city, U.S.
- Intra-tumoural immunotherapy expert and lead investigator and author in the Phase III T-VEC trial in malignant melanoma
Prof. Sandra Demaria
- M.D., Pathologist, NY, U.S
- Professor of Radiation Oncology and Pathology at Weill Cornell Medicine, Cornell University, New York, NY
- Expertise in the use of local radiotherapy as a strategy to induce in situ vaccination and enhance responses of tumors to immunotherapy. Extensive expertise also in pathology, and especially breast cancer pathology.
Prof. Kevin Harrington
- M.D., PhD, Royal Marsden Hospital / The Institute of Cancer Research, London
- Clinical and radiation oncologist; leader of targeted therapy team at Institute of Cancer biology
- Global Principal Investigator for the Pembrolizumab + T-VEC Phase III trial in Head & Neck cancer
Prof. Holbrook Kohrt
- M.D, PhD, Stanford University, U.S.
- Assistant Professor, Stanford Cancer Institute
- Expert in translational and clinical immune-oncology and co-director of the U.S. cancer immunotherapy trials network.
Prof. Guido Kroemer
- M.D., PhD, Institute Gustave Roussy, Paris, France
- Professor University of Paris Descartes
- Expert in cell biology, cancer research and in translational immunology
Prof. Aurelien Marabelle
- M.D., PhD, Institute Gustave Roussy, Paris France
- Clinical Director, Cancer Immunotherapy Programme, Institute Gustave Roussy, Paris France
Prof. Laurence Zitvogel
- M.D., PhD, Institute Gustave Roussy, Paris, France
- Research Director at INSERM U1015
- A world leader in immune-oncology translational research
Andrew Saunders, CMO of Lytix Biopharma, commented on this:
“Lytix´ Scientific and Clinical Advisory Board members have significant expertise in several fields critical to oncology including translational medicine, immunology, pathology, and radiation, surgical and clinical oncology. Their membership is a strong endorsement of the science and potential of Lytix´ oncolytic peptide immunotherapy LTX-315. We believe their expertise and guidance will be critical to guide the optimal development of this first in class oncolytic peptide immunotherapy.”
About LTX-315
LTX-315 induces a potent stimulation of an extended range of tumour specific T-cells attacking cancer, increasing patient specific immune response. LTX-315 “pushes the accelerator” of the immune system through the release of potent immune stimulants. Furthermore, LTX-315 differentiates from other cancer immunotherapies by inducing the release of an extended range of patient specific tumour antigens.
Lytix Biopharma presented initial safety and efficacy data from the ongoing Phase I monotherapy trial with LTX-315 at the 18th European Cancer Congress (ECC2015) in Vienna on September 26. The immunotherapeutic oncolytic peptide LTX-315 has demonstrated a favorable safety profile and emerging evidence of clinical anti-tumour activity and immune effects. Based on these data and the complementary mode of action to immune checkpoint inhibitors, Lytix Biopharma will proceed with it’s plans to initiate the first combination trial with a check point inhibitor early 2016. Currently 7 active centers and 2 new centers are joining the study in EU. Lytix Biopharma has also filed an IND to initiate US trial participation.